drugset / Trial / NCT02720692

Evaluation of N1539 Following Major Surgery

NCT02720692

Phase 3 Completed 722 enrolled Baudax Bio
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.

Timeline

Start
2016-03
Primary completion
2017-03
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 30 mg Intravenous

Indications

No indication recorded.